Older people who regularly used proton pump inhibitors had a greater risk of mental decline.
A free, open online course on rare forms of Alzheimer’s, Lewy body, and frontotemporal dementia aims to spread knowledge while harnessing social learning.
Newly discovered Aβ effects of this cancer drug may be unrelated to its previously known mechanism of action.
Data from the Framingham Heart Study support the idea that dementia incidence is on the decline, but researchers are still dissecting the factors responsible.
Only mutant transgenes, not wild-type, cause disease.
The jury is out on whether the drug shifts Aβ in people.
AV1451 appears too weak to diagnose non-AD tauopathies.
Inhibiting the Rho kinases ROCK1 and ROCK2 with fasudil, a drug approved in China and Japan, stimulates tau autophagy in cell culture and flies.
A compound ensures the ALS-linked protein SOD1 and the respiratory enzyme COX are sated with the essential metal.
Attendees grapple with conflicting binding results
Scientists find evidence for an Aβ etiology distinct from Alzheimer’s after brain trauma.
Researchers failed to confirm a high-profile, previous 10-lipid panel, but remain bullish on the potential of blood-based metabolites as biomarkers.
Preliminary data suggests a long lag between Aβ and tau deposits as the disease develops.
In hopes of incorporating spatial navigation as an outcome measures in trials, a virtual version of the Morris water maze aims to bridge mouse and human therapy studies.
While regulators are trying to figure out what went wrong, independent chemists have dug into the mechanism of what may have been a "dirty" drug.
No filters selected